Brii Biosciences Limited - Asset Resilience Ratio
Brii Biosciences Limited (7SS) has an Asset Resilience Ratio of 56.48% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Brii Biosciences Limited to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Brii Biosciences Limited's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of Brii Biosciences Limited.
Liquid Assets Composition Over Time
This chart breaks down Brii Biosciences Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read 7SS total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €1.33 Billion | 56.48% |
| Total Liquid Assets | €1.33 Billion | 56.48% |
Asset Resilience Insights
- Very High Liquidity: Brii Biosciences Limited maintains exceptional liquid asset reserves at 56.48% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Brii Biosciences Limited Industry Peers by Asset Resilience Ratio
Compare Brii Biosciences Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH |
Biotechnology | 63.98% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 62.24% |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA |
Biotechnology | 0.00% |
|
Wecome Pharmaceutical Co Ltd
SHE:300878 |
Biotechnology | 0.67% |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX |
Biotechnology | 86.66% |
|
Relmada Therapeutics Inc
NASDAQ:RLMD |
Biotechnology | 95.25% |
|
MediWound Ltd
F:M8W |
Biotechnology | 56.04% |
Annual Asset Resilience Ratio for Brii Biosciences Limited (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Brii Biosciences Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 56.48% | €1.33 Billion ≈ $1.56 Billion |
€2.36 Billion ≈ $2.76 Billion |
+7.82pp |
| 2024-12-31 | 48.66% | €1.32 Billion ≈ $1.54 Billion |
€2.71 Billion ≈ $3.16 Billion |
-19.22pp |
| 2023-12-31 | 67.88% | €2.17 Billion ≈ $2.54 Billion |
€3.20 Billion ≈ $3.74 Billion |
+14.61pp |
| 2022-12-31 | 53.27% | €1.81 Billion ≈ $2.11 Billion |
€3.39 Billion ≈ $3.97 Billion |
+39.44pp |
| 2021-12-31 | 13.83% | €499.65 Million ≈ $584.14 Million |
€3.61 Billion ≈ $4.22 Billion |
+12.26pp |
| 2020-12-31 | 1.58% | €20.00 Million ≈ $23.38 Million |
€1.27 Billion ≈ $1.48 Billion |
-- |
About Brii Biosciences Limited
Brii Biosciences Limited focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, a recombinant protein-based HBV immunotherapeutic candidate; Elebsiran, an investigational subcutaneously administered HBV-targeting siRNA; and Tobevibart, an investigational subcutaneously administered HBV-neut… Read more